Key positive data on monthly HIV regimen offer hope for patients saddled with standard daily pills
HIV patients have much to cheer about this week. After reports that a second HIV patient has experienced sustained remission following a bone marrow transplant, a pair of drugmakers on Thursday posted pivotal data that showed their monthly injectable treatments worked as well as the standard daily three-drug cocktail in suppressing the virus that causes AIDS.
The injectable regimen comprising two drugs — Johnson & Johnson’s $JNJ rilpivirine (sold as Edurant) and ViiV Healthcare’s experimental treatment cabotegravir — was tested in a two late-stage studies in more than 1180 patients altogether. The total dataset will be used to submit applications to market the injectable formulation to regulators later this year, ViiV said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.